Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Jan;59(1):10-6.
doi: 10.1136/jcp.2005.027664.

Altered metabolism and mitochondrial genome in prostate cancer

Affiliations
Review

Altered metabolism and mitochondrial genome in prostate cancer

G D Dakubo et al. J Clin Pathol. 2006 Jan.

Abstract

Mutations in mitochondrial DNA are frequent in cancer and the accompanying mitochondrial dysfunction and altered intermediary metabolism might contribute to, or signal, tumour pathogenesis. The metabolism of human prostate peripheral zone glandular epithelial cells is unique. Compared with many other soft tissues, these glandular epithelial cells accumulate high concentrations of zinc, which inhibits the activity of m-aconitase, an enzyme involved in citrate metabolism through Krebs cycle. This causes Krebs cycle truncation and accumulation of high concentrations of citrate to be secreted in prostatic fluid. The accumulation of zinc also inhibits terminal oxidation. Therefore, these cells exhibit inefficient energy production. In contrast, malignant transformation of the prostate is associated with an early metabolic switch, leading to decreased zinc accumulation and increased citrate oxidation. The efficient energy production in these transformed cells implies increased electron transport chain activity, increased oxygen consumption, and perhaps, excess reactive oxygen species (ROS) production compared with normal prostate epithelial cells. Because ROS have deleterious effects on DNA, proteins, and lipids, the altered intermediary metabolism may be linked with ROS production and accelerated mitochondrial DNA mutations in prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Genesis Genomics Inc (GGI) supported this work. GDD, RLP, and RET hold stock options and equity ownership in GGI, and are employed by GGI

References

    1. Nelson W G, De Marzo A M, Isaacs W B. Prostate cancer. N Engl J Med 2003349366–381. - PubMed
    1. Warburg O.The metabolism of tumors. New York: Smith RR, 1931
    1. Carew J S, Huang P. Mitochondrial defects in cancer. Mol Cancer 200219 - PMC - PubMed
    1. Modica‐Napolitano J S, Singh K. Mitochondria as targets for detection and treatment of cancer. Expert Rev Mol Med 200220021–19. - PubMed
    1. Augenlicht L H, Heerdt B G. Mitochondria: integrators in tumorigenesis? Nat Genet 200128104–105. - PubMed

Publication types